Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic cd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro Natural killer (NK) cell lymphomas/leukemias are rare neoplasms with an aggressive clinical behavior. The majority of the cases belong to extranodal NK/T-cell lymphoma, nasal type (ENKTL) in the current WHO classification scheme. Geneexpression profiling (GEP) of 21 ENKTL and NK-cell lymphoma/ leukemia patients, 17 NK-and T-cell lines and 5 indolent NK-cell large-granular-lymphocytic proliferation was performed and compared with 125 peripheral T-cell lymphoma (PTCL) patients previously studied. The molecular classifier derived for ENKTL patients was comprised of 84 transcripts with the majority of them contributed by the neoplastic NK cells. The classifier also identified a set of cd-PTCLs both in the ENKTL cases as well as in cases initially classified as PTCL-not otherwise specified. These cd-PTCLs expressed transcripts associated with the T-cell receptor (TCR)/CD3 complex, suggesting T cell rather than NK-cell lineage. They were very similar to NK-cell tumors by GEP, but were distinct from cytotoxic (ab)-PTCL and hepatosplenic T-cell lymphoma, indicating derivation from an ontogenically and functionally distinct subset of cd T cells. They showed distinct expression of Vc9, Vd2 transcripts and were positive for TCRc, but negative for TCRb by immunohistochemistry. Targeted inhibition of two oncogenic pathways (AURKA and NOTCH-1) by small-molecular inhibitors induced significant growth arrest in NK-cell lines, thus providing a rationale for clinical trials of these inhibitors in NK-cell malignancies.
Introduction
Natural killer (NK)-cell malignancies are rare and present mainly as a lymphoma and less commonly as leukemia termed aggressive NK-cell leukemia (ANKL).
1 Extranodal NK-cell lymphoma typically occurs in the nasal/paranasal areas with prominent angioinvasion and angiodestruction and accompanying necrosis. Other extranodal sites may also be involved and are frequently associated with hemophagocytic syndrome at the advanced stage. 2 There have also been reports of rare T-cell lymphomas in these locations with very similar clinicopathologic features, and these lesions are grouped under the heading of extranodal NK/T-cell lymphoma, nasal type (ENKTL). 3 ENKTL shows strong geographic predilection, with much higher frequencies in East Asia and Central and South America. 4 ANKL is a related disorder with highly aggressive clinical course in contrast to the chronic lymphoproliferative disorder of NK cells. 5 Although ENKTL localized to the nasal region is responsive to radiation therapy, patients with disseminated disease have a very poor outcome. 6, 7 There is a spectrum of lymphomas with cytotoxic (CT) molecules belonging to ab or gd T-cell lineage 8 including hepatosplenic gd T-cell lymphomas (HSTCL), 9 enteropathyassociated T-cell lymphoma (EATCL) 10 and CT T-cell lymphoma of the skin and subcutaneous tissue. 11, 12 These tumors express the surface T-cell receptor (TCR)/CD3 complex, exhibit clonal TCR rearrangement and are negative for Epstein-Barr virus (EBV) genome in the tumor cells. It is unclear if these entities have distinct gene expression profiles (GEPs) that can distinguish them from each other and from ENKTL.
Owing to the rarity of the disease and the difficulty in obtaining adequate biopsy specimens, the molecular mechanisms underlining ENKTL are largely unknown. Only a few genome-wide profiling studies using NK-cell lines 13, 14 and a limited number of NK-cell 15 and gd T-cell lymphoma cases have been performed. 16 In this study, we have defined molecular signatures for ENKTL and related malignancies. We have also identified a number of oncogenic pathways in NK-cell tumors and validated the potential significance of the Notch-1 and aurora kinase A pathways by inhibitor studies in vitro.
Materials and methods

Patient source and cell lines
A series of ENKTL (n ¼ 18), ANKL cases (n ¼ 2) and an EBV (À) aggressive NK-cell lymphoma (n ¼ 1) diagnosed pathologically were studied 4, 7 for their GEP. We compared their GEP with a series of peripheral T-cell lymphoma (PTCL) cases from our recent study 17 including 44 PTCL-not otherwise specified (NOS) cases, 4 HSTCL, 2 EATCL cases, 11 CT (ab)-PTCL 17 and five indolent NK-cell large-granular-lymphocytic proliferation cases. The pathology review, diagnostic criteria and clinical data for these cases have been described. 4, 7 The Institutional Review Board of the University of Nebraska Medical Center approved this study.
The characteristics of malignant NK-cell lines, gd T-cell lines 18 and other T-cell lines are summarized in Supplementary  Table 1a . The cell lines were cultured as previously described. 17 Normal resting and activated NK cells, 19 and T-cell subsets were used for comparative analysis.
RNA isolation and GEP
We used HG-U133 plus 2 arrays (Affymetrix Inc., Santa Clara, CA, USA) for GEP as described previously. 17 The raw data was uploaded in BRB-ArrayTools (version 3.7.0) 20 for analysis. The classifier for ENKTL was constructed using the Bayesian algorithm as described earlier. 21 We selected genes at a significance level (Po0.001) and a mean fold difference (X4-fold ) between the ENKTL and PTCL groups for the Bayesian algorithm. Classification precisions were evaluated using leave-one-out cross-validation. 20 Differential gene-expression and pathway analysis was performed using random-variance T-test (Po0.005), significance analysis of microarrays (with false discover rate o0.1 and X3-fold change) 22 and geneset-enrichment-analysis computational programs. 23 The microarray data is available in the Gene Expression Omnibus database of NCBI through the accession numbers GSE19067 and GSE8059.
Evaluation of re-classified cases
The re-classified cases by GEP were re-reviewed by DD Weisenburger. Additional immunostains and TCRg gene rearrangement analyses were performed when feasible to evaluate the diagnoses of these cases. The antibody for TCRg (clone g3.20) (Thermo Scientific/Pierce Biotechnology/Endogen, Rockford, IL, USA) was incubated with the slide for 2 h at 1:80 dilution. Antigen retrieval was performed at 115 1C in 1 mM EDTA (pH 8.0) for 15 min followed by 15 min cooling at room temperature. Immunostaining was performed on the Dako Autostainer using a Dako EnVision Dual Link Peroxidase/DAB detection kit (Dako North America Inc., Carpinteria, CA, USA) and reactive tonsil was used as control.
Clinical correlation
The Kaplan-Meier method was used to estimate overall survival and event-free survival of the patients, and the log-rank test was used to compare the survival distributions. 4 Treatment of NK-cell lines with aurora kinase A (AURKA) and Notch-1 inhibitors NK-cell lines with (SNK6, NKYS and KAI3) or without (KHYG1) EBV were treated with an AURKA inhibitor (MK-8745) (Merck & Co., Inc., Whitehouse Station, NJ, USA). Cell viability was determined using CellTiter-GloLuminescent-Cell Viability Assay (Promega Inc, Madison, WI, USA). Notch-1 inhibitors (Compound-E and Compound-34, ENZO Life-Sciences, Inc, Plymouth Meeting, PA, USA) were similarly tested in NK-cell lines. B-cell line (DHL16) was used as negative and HL (L428) and T-cell line (Jurkat) as positive controls for Notch-1 experiments. AURKA phosphorylation status and co-activators and substrates (TPX2, TP53 and Survivin) were evaluated by western blots (ECL Plus kit; GE-Healthcare Bio-Science, Piscataway, NJ, USA). Apoptosis and cell cycle analysis was performed with flow cytometry 24 (BD FACScalibur, BD-Bioscience, San Jose, CA, USA). Analysis of the list mode data was performed using ModFit software (VeritySoftwarehouse, Topsham, ME, USA).
Results
Patient and cell line characteristics
We have identified four distinct groups of CT lymphomas: NK-cell lineage (NKCL), HSTCL, CT (ab)-PTCL and gd-PTCL (non-hepatosplenic, NHS) according to their lineage and geneexpression profile as detailed in subsequent sections, and their characteristics are summarized in Table 1a . NKCL refers to NK-cell lineage malignancies of ENKTL and ANKL entities. The Figure 1) . The two cases diagnosed with stage-1 disease showed overall survival exceeding 18 years, indicating that the disease may be curable at this stage. The majority of the patients included in this study were from East Asia (B70%) with a male to female ratio of B1:1 and median age at diagnosis of 49 years (range, 24-79 years). The majority of NKCL cases were examined for pan T-and NK-cell markers and showed expression of the NK-cell marker CD56 and cytoplasmic CD3e, but were negative for surface CD3e (Leu4) and TCRg rearrangement (7 of 7, 100%) and other T-cell makers including CD5, CD4 and CD8 (Table 1b) . As expected, these cases also showed positive staining for the CT molecules TIA1 and/or granzyme B (Table 1b) . The major characteristics of the cell lines are summarized in Supplementary (Figure 1 ) and most of the up-regulated genes were essentially contributed by NK cells, as they showed an expression pattern similar to normal NK cells (resting and IL-2 activated) and NK-cell lines (Figure 2c ). These genes included killer cell immunoglobulin-or lectin-like receptor (KIR or KLR) family members, NK-cell-associated markers, CT molecules and a group of distinct chemokines primarily expressed by NK cells or CT T cells. Some of the transcripts were also noted in normal CD8 þ T cells (resting and IL12 activated). TCRd mRNA, but not CD16 (FCGR3A) was represented in the classifier. Certain up-regulated transcripts, encoding KRT19 (mainly expressed in endothelial cells) and VSIG4 (macrophages) were absent from the NK-cell lines and normal NK cells, implying their derivation from stromal cells ( Table 2 ). The down-regulated genes were largely associated with T-cell biology and stromal components including T-cell markers (CD3 subunits) and genes involved in T-cell differentiation, activation and chemotaxis, transcripts from B cells and macrophages/ dendritic cells. relative level of expression Figure 1 Gene-expression-based molecular predictors for ENKTL. The probability that a case is classified as ENKTL vs PTCL is shown at the top. A small subset of PTCL-NOS cases was re-classified as ENKTL, which, on further examination, showed gd T-cell differentiation. Each column represents a case and each row represents the expression level of a gene. Gene-expression levels are depicted according to the color scale shown.
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The molecular classifier was initially constructed using all pathologically diagnosed ENKTL cases and later evaluated in PTCL cases as well as two ANKL, one EBV(À) NK-cell lymphoma case and five indolent NKLGL. The accuracy of the classifier was evaluated by leave-one-out cross validation (LOOCV) and was robust in re-classifying 15 of 18 pathological diagnosed ENKTL. The two ANKL cases, the EBV(À) NK-cell lymphoma and NK-cell lines were included by the ENKTL classifier. However, 3 of 3 gd T-cell lines derived from ENKTL, 18 1 EATCL and 4 (5 biopsies) of 44 PTCL-NOS cases were also classified as ENKTL with 490% probability. A small number of PTCL cases (n ¼ 5) showed greater similarity (460-85% probability) to ENKTL, when evaluated with the classifier and included four HSTCL (72-85% probability) and one CT (ab) PTCL (B60% probability). These cases did not show any association with EBV, and when evaluated with significance analysis of microarrays analysis, showed significant geneexpression differences with the cases classified as ENKTL with 490% probability (see below). The three molecularly unclassified cases of ENKTL had low expression of NK-cell markers (CD56 and KIR molecules), high expression of endothelial cellrelated genes and did not express other PTCL subtype signatures, suggesting that they had a low number of neoplastic cells.
The four PTCL-NOS cases and one EATCL predicted to be ENKTL with 490% probability were further examined. Interestingly, two transcripts (CD3g and CD3d) were expressed by the re-classified EATCL, PTCL-NOS and two ENKTL cases. Differential gene-expression analysis of the latter group of cases against the remaining cases showed significantly (Po0.005) higher expression of transcripts encoding the TCR complex including CD3g, CD3d, TCRgC2, TCRVg9 and TARP (410-fold), the activation and differentiation molecules (CD69 and LAT2) consistent with T-cell lineage differentiation (Figure 2a ; Supplementary Table 2 ). There was high expression of TCRgV9 and Vd2 that correlates with the high incidence of Vg9 and Vd2 usage reported previously in nasal T-cell lymphoma and chronic EBV infection. 26 We also observed higher expression of IKZF2 (P ¼ 0.0001), a T-cell-restricted IKAROS family member, 27 and T-cell adaptor protein SH2B3 (LNK, P ¼ 0.008) 28 and a repertoire of transcripts encoding KIR molecules (Supplementary Table 2 ). The analysis indicated that this group of cases was T-cell lymphomas expressing the gd TCR. The two ENKTL cases of gd T-cell lineage were positive for EBER, and showed a very similar GEP to three gd T-cell lymphoma lines, 18 as well as the remaining group of 15 cases derived from NK-cell lineage, thus clearly showing the close relationship among the ENKTL cases not only morphologically and clinically, but also in gene expression profiles despite their separate lineage derivation. The ENKTL cases of gd T-cell lineage were also remarkably similar by GEP to the other five re-classified cases (4 PTCL-NOS, 1 EATCL) that are designated as gd-PTCL, (NHS) (see below).
Gene-set-enrichment-analysis identified gene signatures associated with IL12 signaling, proliferation, and chromosome 6q arm in gd T-cell lineage lymphomas compared with NKCL tumors. The analysis of overall survival showed no significant difference between these tumors similar to a previous report. 29 We performed hierarchical clustering of the ENKTL/ANKL, the re-classified gd-PTCL (NHS), CT (ab)-PTCL 17 and four HTSCL cases using the ENKTL classifier. The ENKTL molecular classifier clustered the re-classified gd-PTCL with ENKTL cases in one cluster as they showed very similar expression profile (Figure 2b and c), whereas the CT (ab)-PTCL and HSTCL clustered separately.
The re-classified gd-PTCL (NHS) from PTCL-NOS cases showed extranodal involvement including skin (n ¼ 2), lung (n ¼ 1) or neck LN (n ¼ 1) and with a CD3 þ and TCRb (bF1) negative immunohistochemical profile, when examined, consistent with gd T-cell lineage (Supplementary Table 3 ). CD56 protein expression was not consistent (1 of 2 cases positive), and two of the four cases showed CD56 mRNA expression at a similar range as in NK-cell malignancies. Two of the four cases were double negative for CD4 and CD8, and one case was double positive. Interestingly, 3 of 3 cases were negative for EBV by EBER in situ hybridization. A representative re-classified case is shown to be positive for TCRg by immunohistochemistry (Figure 2d ). The gd-PTCL (NHS) originally classified as EATCL
HSTCL NKCL / -PTCL(NHS)/ -ENKTL NK-/ Tcell lines CT( )-PTCL T-cell lines b a
(NKCL refers only to lymphomas of NK-cell lineage including ENKTL and, ANKL and γδ-T represent two cases of ENKTL with γδ T-cell lineage)
Representative transcripts
Molecularly defined
Median expression (NKp30) and KLRK1(NKG2D), NK-cell activation markers and genes critical for CT function were highly expressed in NKCL (Table 2) . NKCL showed a limited cytokine profile, with cytokines mainly involved in angiogenesis (IL8 and CXCL17), migration of monocytes/macrophages (CCL-8,-7,-4, CXCR3) and the pro-inflammatory response (INFg). There were many downregulated genes relevant to T-cell biology as mentioned above.
Hepatosplenic gd T-cell lymphomas. The four cases of this rare lymphoma formed a distinct hierarchical cluster, but showed similarity to ENKTL (70-85% probability with the classifier). The differentially expressed transcripts showed the characteristic anatomical (liver/spleen) distribution of the neoplastic cells, with high expression of metabolism and B-cell-related genes. Even without the liver/splenic signature, HSTCL has a distinct GEP reflecting T-cell biology and its gd T-cell derivation. It has lower expression of genes involved with cytotoxicity including GZM-A,-M, and Table 4 ). When gd-PTCL (NHS) subtype was compared with HSTCL, similar differential expression as noted with NKCL was observed aside from the TCR complex-related transcripts. Notably, the CT molecules GNLY (33-fold), GZMB (11-fold), GZMM (4-fold) and transcription factor TWIST1 (19-fold) previously shown to be highly expressed in Sézary syndrome 30 and pan T-cell marker CD7 (8-fold) were significantly up-regulated in gd-PTCL (NHS).
Gene-set-enrichment-analysis also showed significant enrichment of proliferation-related gene signatures with NHS gd-PTCL, whereas gene signatures associated with angiogenesis, liver metabolism and B-cell-related gene signature were significantly enriched in HSTCL. A notable difference in contrast to the former (NKCL vs HSTCL) comparison was that no significant differential expression of KIR or KLR family members was observed between HSTCL vs gd-PTCL (NHS). Table 5 ). The gd-PTCL (NHS) cases and the two ENKTL of gd T-cell lineage were also molecularly distinct from CT(ab)-PTCL subtype. Aside from the expression of transcripts encoding different TCR chains, the gd-PTCL (NHS) cases exhibited GEP very similar to NK-cell lymphoma including distinct expression of KIR or KLR family members, also observed previously 16 ( Figure 3 ; Supplementary Table 6) . On the contrary, CT(ab)-PTCL showed up-regulated expression of the full repertoire of T-cell markers including co-stimulatory genes (CD27,CD28 and CD82), genes involved in T-cell activation (IKZF1, TCF4), a characteristic group of cytokines/receptors and a higher expression of genes associated with proliferation (Supplementary Figure 3b) .
Identification of activated pathways in NKCL
Several gene signatures (for example angiogenesis, genotoxic stress and proliferation) and signaling pathway (for example TGFb, Notch and Wnt) were significantly enriched in NKCL, when compared with IL2-activated normal NK cells and indolent NK-large-granular-lymphocytic proliferation cases (Table 3) . Surprisingly, the signatures of NF-kB pathway/target genes were not enriched in NKCL.
NK-cell lines are susceptible to Notch and AURKA inhibitor
We investigated the significance of selected up-regulated pathways by observing the effect of inhibiting the relevant pathways on NK-cell lines. The two Notch inhibitors tested are potent inhibitors of g-secretase and Notch processing. Both Table 3 Enriched pathways and gene signatures in NK-cell lineage malignancies 
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inhibitors induced significant concentration-dependent growth inhibition of the NK-cell lines, NKYS and KHYG1, whereas KAI3 was less sensitive (Figure 4a ).
We observed high expression of AURKA mRNA in patient samples and cell lines. The expression of the protein was seen in all NK-lymphoma cell lines (Figure 4b and c) . AURKA is located at a frequently (450%) amplified locus (20q13) in lymphomas derived from NKCL 31 and is involved in multiple pathways, promoting the proliferative function of MYC 32 and WNT signaling, 33 while inhibiting TP53. 34 Moreover, AURKA is upregulated by hypoxia 35 that is frequently observed in ENKTL. Many of these signatures were significantly enriched in ENKTL, for example Myc-induced signature, and WNT signaling and genotoxic pathway (Table 3 ). The active phosphorylated form (p-AURKA) and its substrates (TPX2, TACC3 and EG5) could be shown. We, therefore, tested the NK-cell lines with a novel small-molecule AURKA inhibitor (MK-8745) and all cell lines showed a significant increase in apoptosis and cell cycle arrest (Figure 4d; Supplementary Figure 3a) . This inhibition led to decrease in endogenous p-AURKA and its substrate TPX2, without affecting the level of total AURKA. The downstream target of AURKA, TP53, was significantly induced and there was a gradual decrease in survivin (target of TP53) level with time (Figure 4e ).
Discussion
The clinicopathological features of ENKTL cases included in this study are consistent with previous studies. 7, 36 The immunophenotype of tumor cells showed expression of NK-cell markers including CD56, cytoplasmic CD3e, CT molecules (TIA1 and granzyme B) and presence of EBV in the majority of the cases, consistent with observations that NK-cell is indeed the cell of origin in the majority of ENKTL cases. In keeping with this observation, our molecular classifier included most of the upregulated genes that coded for the distinctive phenotypic and functional characteristics associated with NK cells and showed high specificity in distinguishing NK-cell malignancies including ANKL from most PTCL cases. However, we also identified two cases of gd T-cell lineage in ENKTL, which can be differentiated from their NK-cell counterpart by the high expression of CD3g, CD3d and TCRg-associated transcripts. Despite the difference in cell lineage, these ENKTL cases share very similar morphological and clinical characteristics and as shown in this study, also share a very similar molecular profile. NK-cell neoplasms are characterized by the presence of EBV in tumor cells; however, tumor cases/cell lines without EBV have been reported. 25, [37] [38] [39] [40] In our series, EBV status has no impact on GEP either in tumor specimen or in cell lines.
Our molecular classifier not only identified gd T-cell cases of ENKTL, but also a subset of gd-PTCL (NHS) in other extranodal areas that showed a strikingly similar GEP to NK cells, NK-cell lines and to gd T-cell lines derived from ENKTL. 18 The geneset-enrichment-analysis findings of chromosome 6q gene enrichment in gd-PTCL (NHS) compared with NKCL is likely related to the frequent deletion of 6q in the NK-cell counterpart. 31 This deletion is not observed in the gd T-cell lines, 41 and may be similarly true for gd-PTCLs (NHS) as well. Gene signatures associated with IL12 signaling, shown to be critical for gd T-cell proliferation by resisting apoptosis, 42 were up-regulated in gd-PTCL (NHS) compared with NKCL. The immunohistochemical staining and pathology review provided further evidence for gd T-cell lineage in these cases. The gd-PTCL (NHS) case presenting in the skin in our study resemble the primary cutaneous gd T-cell lymphoma as defined in the current WHO. 3 It would be of interest to study more cases of primary cutaneous gd T-cell lymphomas to determine whether they also share the GEP of the gd-PTCL (NHS) cases we have defined in this study.
The term mucocutaneous or NHS gd-PTCL mentioned in the WHO-EORTC classification scheme 12 would encompass the cases of gd-PTCL described here, although the heterogeneity within this group of disorders has not been defined. Normal gd T cells are enriched in mucosal surfaces 43 and exhibit many of the characteristics of the innate immune system similar to NK cells. 44 There are subsets of gd T cells that differ in their ontogeny as reflected by their time of appearance in the thymus, TCR gene usage, TCR combinatorial complexity and their locations and functions in the body. There is also corresponding preferential gd gene usage in gd-PTCL at different sites such as Vd1 in HSTCL 9, 45 , Vd2 in primary cutaneous gd-PTCL 46 and Vg9Vd2 in ENKTL and gd-PTCL (NHS). 26, 29 Consistent with these findings, the re-classified gd-PTCLs in this study exhibited extranodal disease and expressed Vg9, Vd2 mRNA at high levels. Different organ sites may be populated preferentially at different stages of development by gd T-cell populations and there is likely to be further heterogeneity in the mucocutaneous gd-PTCL. Therefore, a detailed study of a large series of gd T-cell lymphomas from different sites is needed to decipher the molecular relationship among these gd T-cell lymphomas.
The HSTCL appears to be distinct clinically, pathologically and by GEP from NKCL and gd-PTCL of mucocutaneous sites presented in this study as also suggested by a previous observation. 47 Even after excluding the signatures contributed by the liver and spleen, or the differences in TCR usage, NKCL and gd-PTCL (NHS) exhibit distinct GEP, especially the CT profile with HSTCL expressing TIA-1, but not PRF, GZMA and GZMM. These observations suggest diseases derived from gd T cells in hepatosplenic and NHS sites are distinct. 16 It is possible that the gd-PTCL (NHS) observed in this study are derived from a unique subset of gd T cells with features very similar to NK cells compared with other gd-PTCL. It is also probable that the clinicopathological and GEP characteristics of these gd-PTCL are influenced by the microenvironment in which they are derived. These hypotheses need to be further tested by studying the TCR usage/sequence and the GEP of diverse subtypes of gd-PTCL.
The NKCL shows a distinct GEP compared with CT(ab)-PTCL defined previously. 17 The re-classified gd-PTCL (NHS) and HSTCL are also distinct from CT(ab)-PTCL. The latter entity exhibits high levels of TCRa and b transcripts, but not TCRg and d transcripts, and shows more functional characteristic of CD8 þ T cells. These cases tend to be more proliferative and show lower expression of CD56, NCR1 (NKP46) and TCRd mRNA, but high expression of TCR signaling molecules. Clinically, all these CT subtypes of PTCL are highly aggressive and are associated with a short survival.
As patients with NK-cell malignancies have a poor outcome with current therapies, 4 novel approaches are needed to improve survival. Comparison of NKCL with PTCL-NOS yielded mostly pathways that are differentially expressed between NK and T cells and provided little insight into the biology of NKCL. Therefore, we compared NKCL with IL2-activated NK cells and NK-large-granular-lymphocytic proliferation cases. The enrichment of TGFb and other immunosuppressive pathways indicated an immunosuppressive microenvironment in NKCL that favors the survival of EBV infected/transformed NK cells. The significant enrichment of angiogenesis pathways in NKCL may be due the vascular destruction in these tumors resulting in hypoxia and activation of HIF1a. The genotoxic stress responsive gene signature indicated the presence of conditions that may activate TP53 function. TP53 is negatively regulated by MDM2, an E3 ubiquitin ligase and positively by an ubiquitin-specific protease-7 (USP7). 48 EBV nuclear-antigen 1 can stably bind to USP7 and promote TP53 degradation by MDM2. 49 Thus, targeting MDM2 function may provide a therapeutic option in ENTKL.
We also observed activation of WNT and NOTCH-1 pathways that was also described by Huang et al 15 in a series of seven ENKTL cases. We tested two g-secretase inhibitors in NK-cell lines, and observed growth and survival inhibition in the tested NK-cell lines validating the significance of the NOTCH pathway in neoplastic cells. We also tested an AURKA inhibitor as the phosphorylated AURKA (activated form) was present in all NK-cell lines and aside from its role in centrosome regulation and mitotic spindle formation, 50 AURKA can influence multiple signaling pathways that promote oncogenesis. Previous reports have shown that AURKA can phosphorylate TP53 at serine-215 resulting in its inactivation and degradation. 34 It also upregulates MYC and telomerase activity 32 and promotes WNT signaling. 33 Some of these signatures were significantly enriched in NKCL (Table 3) . AURKA is also located at a frequently amplified locus (20q13) in NK-cell lymphoma. 31 The AURKA inhibitor MK-8745 51 induced cell cycle arrest and apoptosis in all NK-cell lines tested. There was a decrease in phosphorylated AURKA level with a concomitant decrease in its regulator TPX2. 52 AURKA inactivation was associated with increased TP53 level and decreased Survivin (TP53 target) level. Survivin is not only an anti-apoptotic factor, it is also essential for proper chromosome segregation and cytokinesis, thus augmenting AURKA. 53 These molecular events converge to induce cell cycle arrest and increased apoptosis. These findings suggest that MK-8745 could be a novel therapeutic agent for NK-cellderived lymphomas.
In conclusion our molecular classifier identified lymphomas originating from NK cells as well as a subset of gd T-cell with a very similar gene-expression profile to NK cells. These gd PTCLs have distinct GEP compared with CT(ab)-PTCLs and HSTCL and may be derived from an ontogenically and functionally distinct subset of gd T cells. The Gene set enrichment analysis indicated an immunosuppressive microenvironment, genotoxic stress, angiogenesis and activation of NOTCH, and WNT signaling in ENKTL. The Notch inhibitors could inhibit growth of NK-cell lines, but the AURKA inhibitor was more effective probably because it affected multiple pathways. Pathway analysis and testing can rationally identify promising candidates for therapeutic trials in ENKTL.
